FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response	: 0.5							

	Check this box if no longer subject
	to Section 16. Form 4 or Form 5
\cup	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wilderotter Mary Agnes				2. Issuer Name and Ticker or Trading Symbol Sana Biotechnology, Inc. [SANA]								(Che	elationshi eck all app	ng Person(s) to Issuer						
(Last)	(Fir	rst) (M	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/05/2023								Office belov	er (give title v)		her (s low)	pecify		
C/O SANA BIOTECHNOLOGY, INC. 188 EAST BLAINE STREET, SUITE 400			4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street)	E W	A 9	8102										X Form filed by One Reporting Person Form filed by More than One Reporting Person							
,							Rule 10b5-1(c) Transaction Indication													
(City)	(St	ate) (Z	Zip)		Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See								nt to a co	ontract, inst	truction or wr	itten plan tha	t is inte	ended to		
		Table	I - No	n-Deriva	tive S	ecur	ities Acc	uired,	Dis	posed of	, or	Ben	eficia	lly Owr	ned					
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day				Execution Date,						ies Acquired (A) Of (D) (Instr. 3, 4			Benefi Owned Follow	ties cially I ing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A (D	A) or D)	Price		ted action(s) 3 and 4)					
Common	Stock			07/05/2	2023			A		1,245(1)		A	\$0.00	3	,559	D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execut rity or Exercise (Month/Day/Year) if any		eemed tion Date, n/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4		f S g (I	. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: y Direct (D) or Indirect (I) (Instr.	(D) irect	Beneficial Ownership t (Instr. 4)			
					Code	v	(A) (D)	Date Exercisa	able	Expiration Date	Title	or Nur of	ount mber ares							

Explanation of Responses:

1. Consists of fully vested restricted stock units.

Remarks:

/s/ Julie Shah, Attorney-in-

Fact for Mary Agnes

07/06/2023

Wilderotter

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.